Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bain Capital
Biotech
Bain-backed Angitia drops lead spinal fusion candidate
The musculoskeletal outfit has scrapped AGA111, terminating a phase 3 study of the recombinant protein in patients undergoing spinal fusion surgery.
Darren Incorvaia
Jun 30, 2026 4:56pm
Beeline bolsters autoimmune ambitions with $126M
Jun 30, 2026 7:00am
Bain-backed Beeline buzzes out of stealth with $300M
Apr 15, 2026 7:00am
PitchBook expects disciplined biopharma VC recovery in 2026
Feb 16, 2026 12:01am
Schizophrenia-minded Syremis takes off with $165M series A
Dec 18, 2025 12:59pm
Kailera raises hefty $600M to take Zepbound rival into ph. 3
Oct 14, 2025 9:20am
